- Fee assured
- Verified this account
This healthcare professional let us know that they are currently:
- Accepting new patients
- Available for:
- Face-to-face consultations
- Phone consultations
- Video consultations
Last updated: 29 Jun 2020
- Upper GI
I am a research-active consultant who trained in medical oncology at the Northern Ireland Cancer Centre and Royal Marsden NHS Foundation Trust London. After working as a Locum consultant at Royal Marsden for 21 months, I took substantive consultant position in Gastrointestinal Oncology at UCLH. I also attends North Middlesex University Hospital (NMUH), where I am the Clinical Lead of Carcinoma of Unknown Primary (CUP) and clinical research in Oncology.
I was awarded Robert McAlpine fellowship and studied mechanisms of response and resistance to targeted therapies in advanced colorectal cancer. I gained MD(Res) degree under supervision of Professor David Cunningham at the Institute of Cancer Research and the Royal Marsden Hospital. I was involved in setup and conduct of large multi-centre academic and translational studies from the time that he spent in full-time research, which included working as trial physician for phase II/III studies in early and advanced gastrointestinal cancers.
In collaboration with Professor Cunningham, I secured funding from industry to run an academic phase II study of a multikinase inhibitor in metastatic refractory colorectal cancer. I also wrote a successful application for NIHR portfolio adoption of this study. My main research interests involve stratification of therapies in patients with gastrointestinal malignancies, by setting up studies of clinical and translational relevance.
I have presented and lectured in international conferences and public forums respectively. I published several high impact papers in peer-reviewed journals including Science, Cancer Discovery, Cancer Cell, Gut, Gastroenterologist, Clinical Cancer Research, Oncogene, Oncologist, BMC Cancer, British Medical Journal (BMJ) and British Journal of Cancer. I also served as expert member of National Research and Ethics Committee.
I have also played an active role in improving the educational experience of the junior doctors nationally. I write questions for MRCP(UK) and Medical Oncology exams, and remain part of the national medical oncology recruitment panel.
Areas of interest
Carcinoma of Unknown Primary
Cholangiocarcinoma (Bile duct Cancer)
Gall Bladder Cancer
Current NHS consultant posts held
University College London Hospitals
North Middlesex University Hospital
1) Identification of response and resistance to systemic therapies in GI cancers
2) Integration of liquid biopsies in clinical practice
3) Drug development in GI cancers
4) targeted therapies in GI cancers
5) Genomic profiling of tumours
6) Peronalised medicine
Reading, Writing, Cricket, Squash
(Additional) Languages spoken
- Hindi - Fluent
- Urdu - Fluent
Woolston A*, Khan K.H*, et al. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer. Accepted by Cancer Cell in April 2019
Khan K.H, Rane J, Cunningham D, Chau I, Rao S, Watkins D, Starling N, Kalaitzaki E, Foster M, Braconi C, Valeri N, Gerlinger M, and Chau I. Efficacy and cardiotoxic safety profile of Raltitrexed in Fluorouracil pre-treated or high-risk cardiac patients with GI malignancies- A large single-centre experience. Clinical Colorectal Cancer. 2019;18(1):64-71.
Anandappa G, Lampis A, Cunningham D, Khan K.H, et al. MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial. Clinical Cancer Research. 2019; Apr 5. Pii: clincanres. 3769.2018. doi: 10.1158/1078-0432.CCR-18-3769.
Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K.H, et al. CEA Expression Heterogeneity and Plasticity Confer Resistance to the CEA-Targeting Bispecific Immunotherapy Antibody Cibisatamab (CEA-TCB) in Patient-Derived Colorectal Cancer Organoids.J Immunother Cancer. 2019; 15;7(1):101.
Khan K.H, Cunningham D, Werner B, et al. Forecasting the evolution of resistance to targeted treatment in metastatic colorectal cancer using longitudinal matched tissue and liquid biopsies in a prospective clinical trial. Cancer Discovery. 2018; 8(10):1270-1285.
Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K.H, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359(6378): 920-926.
Khan K.H, Rata M, Cunningham D, et al. “Radiological and circulating biomarkers of response to Regorafenib in treatment-refractory metastatic colorectal cancer patients in a PROSPECTive phase II study(PROSPECT-R)”. GUT 2018; 67(8):1484-1492 .
Khan K.H, Athauda A, Aitken K, et al. Survival Outcomes in Asymptomatic Patients with Normal Conventional Imaging but Raised CEA Levels in Colorectal Cancer Following PET-CT Imaging. Oncologist. 2016; 21(12): 1502-1508.
Khan K.H, Wong M, Rihawi K, et al. Hyperglycaemia and PI3K, AKT and mTOR inhibitors in phase I trials: incidence, predictive factors and management. Oncologist. 2016; 21(7): 855-60.
Courses offered to GPs
- MRCP (UK) Royal College of Physicians 2007
- MRCP (Medical Oncology) Royal College of Physicians 2010
- Dip Oncology NewCastle University Hospital 2013
- MD (Res) Institute of Cancer Research, University of London 2018
Reference number 6058214
Details of entry to specialist register
- Khurum Khan, 2013
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.